Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis
Published in: | ESMO Open |
---|---|
Main Authors: | , , , , , , |
Format: | Text |
Language: | English |
Published: |
BMJ Publishing Group
2017
|
Subjects: | |
Online Access: | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703383/ http://www.ncbi.nlm.nih.gov/pubmed/29209527 https://doi.org/10.1136/esmoopen-2017-000222 |
Description not available. |